Doxazosin for the management of distal-ureteral stones

J Endourol. 2007 May;21(5):538-41. doi: 10.1089/end.2006.0107.

Abstract

Purpose: To evaluate the efficacy of doxazosin in inducing spontaneous passage of stones in the distal ureter and to compare its efficacy according to the size of the stone.

Patients and methods: Seventy-three patients with a mean age of 46.38 +/- 10.17 years who presented with a distal-ureteral stone were divided into four groups according to stone size and drug treatment: <5 mm without doxazosin (group A; n=15); 5-10 mm (group B; n=16); <5 mm with doxazosin 4 mg/day for 4 weeks (group C; n=20); and 5-10 mm with doxazosin 4 mg/day for 4 weeks (group D; n=22). Groups A and B served as controls for groups C and D, respectively.

Results: Spontaneous stone passage was documented in 9 patients (60%) in group A v 17 (85%) in group C (P=0.047) and 7 (43.75%) in group B v 16 (72.73%) in group D (P=0.036). The average expulsion time was 8.78 +/- 1.09 days in group A v 7.59 +/- 0.80 days in group C (P=0.004) and 12.14 +/- 1.35 days in group B v 7.06 +/- 1.29 days in group D (P<0.0001). The number of pain episodes in group D patients was significantly lower than in group B (P +/- 0.0078).

Conclusions: Doxazosin treatment proved to be safe and effective for distal-ureteral stones, as determined by earlier expulsion, decreased colic frequency, and absence of side effects. The efficacy of doxazosin was significantly higher for 5-to 10-mm stones than for smaller ones.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adrenergic alpha-Antagonists / administration & dosage*
  • Adult
  • Colic / drug therapy
  • Colic / pathology
  • Doxazosin / administration & dosage*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Models, Statistical
  • Sample Size
  • Treatment Outcome
  • Ureteral Calculi / drug therapy*
  • Ureteral Calculi / pathology*

Substances

  • Adrenergic alpha-Antagonists
  • Doxazosin